BioSpace News Archive

Saniona (OMX: SANION), a clinical-stage biopharmaceutical company focused on rare diseases, today announced the initiation of a Phase 2b clinical trial of Tesomet in patients with Prader-Willi syndrome (PWS).

Rational Vaccines, today announced preclinical research suggesting that the Company’s herpes simplex virus type 1 (HSV-1) vaccine candidate can protect against herpetic keratitis (HK), a leading infectious cause of blindness in developed countries.

The Children’s Heart Foundation (CHF), the nation’s leading organization dedicated to funding congenital heart defect (CHD) research, will fund over $1,000,000 of research and scientific collaborations in 2021.

Sosei Group Corporation, announced its Chief Financial Officer, Chris Cargill, will present at the 40th Annual J.P. Morgan Healthcare Conference, which will take place virtually, on Monday, January 10, 2022.

Telos Partners LLC is pleased to welcome Scott Day to the position of Senior VP and General Manager.

Zimmer Biomet Holdings, Inc. today announced that Chairman, President and CEO Bryan Hanson and Executive Vice President and CFO Suky Upadhyay will be presenting at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at 3:00 p.m. Eastern Time.

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has submitted a New Drug Application (NDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) for valemetostat, a potential first-in-class dual inhibitor of EZH1 and EZH2, for the treatment of patients with relapsed/refractory adult T-cell leukemia/lymphoma (ATL).

PharmaCyte Biotech, Inc. today announced that it has successfully completed a 36-month stability study of the cells from its Master Cell Bank (MCB).

Aditxt Inc. has signed a share exchange agreement to acquire AiPharma Global Holdings LLC, a wholly-owned subsidiary of AiPharma Group Ltd.

Petros Pharmaceuticals, Inc. today announced the closing of its previously announced registered direct offering and private placement with the company’s largest investor and other existing investors for gross proceeds of approximately $7.5 million.